

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	<p>(a) Indicate the study's design with a commonly used term in the title or the abstract Page 2 line 6</p> <p>(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2</p>
Introduction		
Background/rationale	2	<p>Explain the scientific background and rationale for the investigation being reported Page 3</p>
Objectives	3	<p>State specific objectives, including any prespecified hypotheses Page 3 lines 13-15</p>
Methods		
Study design	4	<p>Present key elements of study design early in the paper Page 4</p>
Setting	5	<p>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 4</p>
Participants	6	<p>(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page 4</p> <p>(b) For matched studies, give matching criteria and number of exposed and unexposed N/A</p>
Variables	7	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 4-5</p>
Data sources/ measurement	8*	<p>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 4-5</p>
Bias	9	<p>Describe any efforts to address potential sources of bias Page 9-10</p>
Study size	10	<p>Explain how the study size was arrived at Page 4</p>
Quantitative variables	11	<p>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 4-5</p>
Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding Page 5-6</p> <p>(b) Describe any methods used to examine subgroups and interactions Page 5-6</p> <p>(c) Explain how missing data were addressed N/a</p> <p>(d) If applicable, explain how loss to follow-up was addressed N/a</p> <p>(e) Describe any sensitivity analyses Page 5-6</p>

Results		
Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <p>Page 7</p> <p>(b) Give reasons for non-participation at each stage</p> <p>N/a</p> <p>(c) Consider use of a flow diagram</p> <p>N/a</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</p> <p>Table 1</p> <p>(b) Indicate number of participants with missing data for each variable of interest</p> <p>N/a</p> <p>(c) Summarise follow-up time (eg, average and total amount)</p> <p>N/a</p>
Outcome data	15*	<p>Report numbers of outcome events or summary measures over time</p> <p>N/a</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>Tables 2-5</p> <p>(b) Report category boundaries when continuous variables were categorized</p> <p>N/a</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p> <p>N/a</p>
Other analyses	17	<p>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</p> <p>Table 5</p>
Discussion		
Key results	18	<p>Summarise key results with reference to study objectives</p> <p>Page 9-10</p>
Limitations	19	<p>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias</p> <p>Page 9-10</p>
Interpretation	20	<p>Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence</p> <p>Page 9-10</p>
Generalisability	21	<p>Discuss the generalisability (external validity) of the study results</p> <p>Page 9-10</p>
Other information		
Funding	22	<p>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based</p> <p>N/a</p>

*Give information separately for exposed and unexposed groups.